12:00 AM
May 19, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ceftaroline fosamil: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-5990, which was in Phase I testing to treat MRSA infection. The company said the antibiotic did not meet its criteria in a Phase I trial, but did not...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >